Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin

Rita Teixeira-Santos1, Elisabete Ricardo2, Ricardo J Branco3

  • 1Department of Microbiology, Faculty of Medicine, University of Porto Porto, Portugal.

Frontiers in Microbiology
|September 29, 2016
PubMed

Insights

This study shows that colistin (CST) enhances liposomal amphotericin B (L-AMB) antifungal activity against Candida and Aspergillus. Their combination forms a stable complex, increasing L-AMB

Area of Science:

  • Mycology
  • Pharmacology
  • Computational Biology

Background:

  • Drug interactions between antifungals and antibacterials are clinically relevant but poorly understood.
  • Liposomal amphotericin B (L-AMB) is a critical antifungal agent.
  • Co-administration of antimicrobials necessitates evaluating potential drug interactions.

Purpose of the Study:

  • To investigate the synergistic effects of L-AMB combined with various antibacterial agents.
  • To characterize the physiological and molecular interactions of synergistic L-AMB combinations.
  • To determine the impact on Candida and Aspergillus species.

Main Methods:

  • Minimal Inhibitory Concentration (MIC) assays of L-AMB in the presence of different concentrations of six antibacterial agents.
  • Fungal viability assays, membrane permeability, metabolic activity, and ROS production measurements.
  • Computational molecular dynamics simulations to elucidate molecular interactions.

Main Results:

  • Colistin (CST) demonstrated the most significant synergy with L-AMB across all tested fungal strains.
  • L-AMB/CST combination significantly reduced fungal viability and increased membrane permeability.
  • Molecular dynamics revealed a stable complex formation between L-AMB and CST, enhancing membrane intercalation.

Conclusions:

  • Colistin exhibits strong synergistic antifungal activity with liposomal amphotericin B.
  • The L-AMB/CST complex enhances L-AMB's fungicidal efficacy at lower concentrations.
  • This combination holds promise for treating invasive fungal infections in polymedicated patients.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
605
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
70